**************************************************************

MusclePharm Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, appointed Mariel Selbovitz, MPH, as Director of Global Therapeutics Product Procurement Development.

“We are thrilled to have Ms. Selbovitz join the MusclePharm team as we enter the therapeutic, nutritional supplementation market that is focused on products to meet the nutritional requirements of people living with HIV/AIDS,” stated Cory Gregory, MusclePharm’s President. “MusclePharm is working to greatly expand our sales of therapeutic, nutritional supplementation and provide increased help to people in need across the globe.”

Mr. Gregory continued, “We believe Ms. Selbovitz expertise and experience in the field of HIV will assist us secure distribution of MusclePharm products, such as Recon, to people living with the HIV disease in developing nations thru The Global Fund to Fight AIDS, Tuberculosis and Malaria, and The Presidents Emergency Plan for AIDS Relief (PEPFAR).”

The Global Fund to Fight AIDS, Tuberculosis and Malaria is an international financing institution that invests the world’s money to battle disease. To date, it has committed US$19.3 billion in 144 countries to support large-scale prevention, treatment and care programs against these three diseases.

“With Ms. Selbovitz extensive experience and assistance we plan to reach millions of people living with HIV in developing nations,” stated Dr. Roscoe Moore, former United States Surgeon General, and Chief Science Director for MusclePharm. “Participating in programs such as the Global Fund and PEPFAR and will enable MusclePharm to help counteract some of the devastating effects of HIV related nutritional deficiencies which greatly affect the immune system, as well as the growth and retention of muscle mass.”

Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced today that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.

Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

“We are very excited to be acquiring Rozetta-Cell Life Sciences,” stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. “Rozetta-Cell brings us a tremendous amount of complementary adult stem cell therapy technology, know-how and experience. With the addition of Rozetta-Cell, Power3 will significantly strengthen its IP portfolio in a major growth market by merging regenerative medicine with the technologies that we are using to identify disease-specific protein biomarkers and develop them into screening and diagnostic tests to address unmet medical needs.”

Forrester Research, Inc., (Nasdaq: FORR) will host three new role-focused Forums, furthering the company’s commitment to serving IT, marketing, and technology industry professionals through a role-based strategy. Forrester’s CIO Forum, Business Process & Application Delivery Forum, and Content & Collaboration Forum will take place October 7-8, 2010 at Gaylord National Resort & Convention Center in Washington, D.C.

“Role-based events are just one of the ways in which Forrester is positioned to address the unique challenges IT professionals face when trying to balance their day-to-day job with staying in front of the next big wave of technology change,” said Julie Meringer, managing director of Forrester’s IT client group. “Our focus on business technology enables attendees to capitalize on these changes and radically rethink the way they implement and manage IT.”

Forrester Research, Inc. is an independent research company that provides pragmatic and forward-thinking advice to global leaders in business and technology. Forrester works with professionals in 19 key roles at major companies providing proprietary research, customer insight, consulting, events, and peer-to-peer executive programs. For more than 27 years, Forrester has been making IT, marketing, and technology industry leaders successful every day.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp.(MSLP.OB).

**************************************************************

Power 3 Medical Products Inc. (OTC:PWRM) has recently unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE:PFE), Exelon (Rivastigmine, Novartis – NYSE:NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE:FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

PWRM, a development stage company, engages in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, amyotrophic lateral sclerosis (ALS), Alzheimers disease, and Parkinsons disease.

PAREXEL International Corporation (Nasdaq:PRXL), subsidiary Perceptive Informatics, a leading eClinical solutions provider, recently reported the results of a survey conducted during its recent webinar entitled “Using Advanced Functionality of EDC to Simplify Workflow.” Perceptive polled biopharmaceutical industry professionals across a broad range of clinical and IT functions about the value of technological advances related to the increased use of Electronic Data Capture (EDC) in clinical development.

Survey results revealed the majority of respondents (66%) believe that the most valuable technological advance related to EDC is the convergence of systems to minimize redundant data entry at sites. A smaller group of respondents (26%) cited the value of dashboard reports available through EDC to enable greater visibility into trial performance metric data. Other EDC-related advances noted by survey participants included single sign-on for systems used at sites and web-enabled designer tools to facilitate collaboration.

According to Bill Byrom, Ph.D., Senior Director, Product Strategy, Perceptive Informatics, “From a clinical site user’s perspective, the EDC system represents the primary solution that performs patient-related tasks such as data collection. In studies using more than one technology, a user may need to log into other solutions to perform related activities. While data integration can eliminate a level of inefficiency and duplication between systems, there is still a need to log in and out of different applications within a single clinical trial. Our survey results indicate that site users benefit from a more streamlined approach to simplify their workflow. Product convergence, which is changing the way technologies can be used together, makes the clinical trial process more efficient by allowing the functionality that exists in one application to be accessed through another.”

The webinar examined how EDC systems are advancing to include new features that enable sponsors to rapidly collect cleaner clinical data and reduce training costs. The benefits of converging Randomization and Trial Supply Management (RTSM) technologies with EDC systems to streamline workflow and the value of integrating real-time ePRO data with EDC systems were discussed, as well as the utility of dashboards to view overall study performance.

Forrester Research, Inc., (Nasdaq: FORR) will host three new role-focused Forums, furthering the company’s commitment to serving IT, marketing, and technology industry professionals through a role-based strategy. Forrester’s CIO Forum, Business Process & Application Delivery Forum, and Content & Collaboration Forum will take place October 7-8, 2010 at Gaylord National Resort & Convention Center in Washington, D.C.

“Role-based events are just one of the ways in which Forrester is positioned to address the unique challenges IT professionals face when trying to balance their day-to-day job with staying in front of the next big wave of technology change,” said Julie Meringer, managing director of Forrester’s IT client group. “Our focus on business technology enables attendees to capitalize on these changes and radically rethink the way they implement and manage IT.”

Forrester Research, Inc. is an independent research company that provides pragmatic and forward-thinking advice to global leaders in business and technology. Forrester works with professionals in 19 key roles at major companies providing proprietary research, customer insight, consulting, events, and peer-to-peer executive programs. For more than 27 years, Forrester has been making IT, marketing, and technology industry leaders successful every day.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)